Business Standard

Gland Pharma Q3 net profit rises 34% at Rs 273 cr

Revenue from operations rose to Rs 1,063 crore in the October-December period of the current fiscal as against Rs 859 crore in the same period of 2020-21 fiscal

Gland Pharma

Press Trust of India New Delhi
Gland Pharma on Friday posted a 34 per cent increase in its consolidated profit after tax at Rs 273 crore for the third quarter ended December 31, 2021, riding on robust sales across various markets.
The Hyderabad-based drug maker had reported a profit after tax (PAT) of Rs 204 crore in the corresponding period of the previous fiscal.
Revenue from operations rose to Rs 1,063 crore in the October-December period of the current fiscal as against Rs 859 crore in the same period of 2020-21 fiscal, Gland Pharma said in a regulatory filing.
"While our key market US grew by 23 per cent during the quarter, our focus on geographical diversification is showing robust results with a y-o-y growth of 88 per cent in the Rest of the World markets during the quarter," Gland Pharma MD & CEO Srinivas Sadu noted.
In alignment with strategic priorities, the company has completed four complex injectable filings and a total of 18 ANDA filings during the quarter, he added.
"We are starting this new year with renewed optimism to accomplish many more milestones," Sadu stated.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 21 2022 | 5:00 PM IST

Explore News